Your Mental Health Amid the Pandemic. Replay June 26 HD Live!

Follow Our Live Coverage of COVID-19 Developments

New Blood Pump System Approved

Maintains circulation during riskier cardiac surgery

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

TUESDAY, March 24, 2015 (HealthDay News) -- The Impella 2.5 System has been approved by the U.S. Food and Drug Administration to maintain stable heart function and blood circulation during high-risk cardiac operations, the agency said in a news release.

The miniature blood pump is sanctioned for coronary artery disease patients during higher-risk procedures such as angioplasty, when a blocked artery is unclogged using an inflated balloon, the agency said.

The system is guided into the left ventricle of the heart via a catheter that's typically inserted into a leg artery. An external controller and monitor turns the pump on and off, measures heart function and allows doctors to adjust the pump as needed, the FDA said.

People with coronary artery disease commonly have diminished blood flow to the heart, which could lead to serious complications during surgery, the agency said.

The Impella System is produced by Abiomed Inc., based in Danvers, Mass.

More information

The FDA has more about this approval.


Last Updated: